Nexien BioPharma Inc. (OTC: NXEN) is a U.S.-based pharmaceutical company focused on developing cannabinoid-based treatments within FDA-compliant pathways. Formerly known as Intiva BioPharma, the company aims to harness cannabis-derived compounds for medical applications.
But with financial instability and halted R&D, does Nexien still have a future, or is it on the verge of collapse? Let’s break it down.
Nexien BioPharma Stock Price Today
- Current Price: $0.0140 (as of March 3, 2025)
- 52-Week Range: $0.0041 – $0.0495
- Year-to-Date Performance: Up 150% from its January 2025 low of $0.0056
Despite its gains, Nexien remains a highly speculative stock with low liquidity and extreme volatility. Investors should approach with caution.
Financial Status: Running on Fumes?
- Working Capital Deficit: $422,691 (as of Dec. 31, 2024)
- Cash Reserves: $1,306 (yes, you read that right)
- Debt & Liabilities: Mounting, with no clear revenue stream
Due to these financial struggles, Nexien paused all R&D activities and is now looking for potential mergers or restructuring opportunities to stay afloat.
Leadership Team: Who’s Steering the Ship?
- Richard S. Greenberg (CEO & Chairman) – Formerly involved with Kanativa, Inc. and Israel Plant Science, Inc.
- Robert I. Goldfarb, JD (COO) – Legal expert, formerly General Counsel at Andrx Corporation.
- Evan Wasoff, CPA (CFO) – Financial expert with experience at Falcon Oil & Gas Ltd.
While experienced, the leadership team faces a serious uphill battle in reviving the company’s prospects.
What’s the Latest With Nexien?
- Last Major Press Release? August 27, 2019. Since then—radio silence.
- Ongoing R&D? Completely suspended due to financial constraints.
- Investor Outlook? Uncertain, with stock volatility and no clear revenue model.
FAQs
Q: What does Nexien BioPharma do?
A: The company focuses on developing cannabinoid-based pharmaceuticals for medical conditions. However, due to financial struggles, all operations are currently at a standstill.
Q: Is NXEN stock a good investment?
A: Given its low cash reserves, halted R&D, and lack of revenue, Nexien is a high-risk penny stock. While the stock has seen gains, its long-term viability is questionable.
Q: Why is Nexien’s stock rising despite financial troubles?
A: The recent 150% increase in 2025 may be due to speculation, low float dynamics, or potential merger rumors. However, without solid fundamentals, the rally may not last.
Q: What’s next for Nexien?
A: The company is exploring mergers or restructuring to survive, but unless new capital is secured, the future remains bleak.
Final Verdict: Buy, Hold, or Avoid?
If you’re looking for a safe, growth-oriented investment, Nexien BioPharma isn’t it. The company is barely staying afloat, and its penny stock status makes it highly volatile. Unless they secure funding or a strong partner, Nexien is in deep trouble.
✅ Speculative traders might find short-term opportunities.
❌ Long-term investors should steer clear unless the company announces significant financial improvements.
Key Takeaways
- Nexien’s stock price is $0.0140 as of March 14, 2025
- The company has halted R&D and is struggling financially
- A merger or restructuring is its best shot at survival
- The stock has gained 150% in 2025 but remains highly risky
Investors should proceed with caution and conduct thorough due diligence before making any decisions.
Mitch Evans is just getting his feet wet as tech reporter but has already had his work published in many major publications including Tech Spot and Android Authority. In regards to academics, Mitch earned a degree in business from Fordham University. Mitch has passion for emerging technology and covers upcoming products and breakthroughs in science and tech.
